All In Biotech

Drug Trial Radar · NCT07205081

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATTO-3712 in Healthy Adult Volunteers and Patients With Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

48

Actual

Start

Oct 22, 2025

Primary completion

Aug 13, 2026

Study completion Aug 13, 2026

Sponsor

Lead sponsor
Attovia Therapeutics IncIndustry
Sponsor type
Industry
First posted
Oct 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic dermatitis. The main questions it aims to answer are: What medical problems do participants have when taking ATTO-3712? How long does ATTO-3712 stay in the body after dosing? Researchers will compare ATTO-3712 to a placebo (a look-alike substance that contains no drug). Participants will be dosed with ATTO-3712 or a placebo, visit the clinic for checkups and tests, and keep a diary of their symptoms.

Conditions

  • Normal Volunteers
  • Atopic Dermatitis (AD)
  • Atopic Eczema
  • Atopic Eczema/Dermatitis (Non-Specific)

Interventions

  • ATTO-3712Drug

    ATTO-3712

  • PlaceboDrug

    Placebo preparation to match ATTO-3712 dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of AEsTime frame: 0-113 Days for SAD; 0-143 Days for MAD
  2. Incidence of laboratory abnormalitiesTime frame: 0-113 Days for SAD; 0-143 days for MAD
  3. Incidence of ECG abnormalitiesTime frame: 0-113 Days for SAD; 0-143 Days for MAD
  4. Incidence of vital sign abnormalitiesTime frame: 0-113 Days for SAD; 0-143 Days for MAD

Locations

17 sites in 3 countries. Site status is shown where the registry gives one.

  • Attovia Clinical Site 203

    Encinitas, California

  • Attovia Clinical Site 209

    Fountain Valley, California

  • Attovia Clinical Site 205

    Huntington Beach, California

  • Attovia Clinical Site 204

    Rocklin, California

  • Attovia Clinical Site 208

    Coral Gables, Florida

  • Attovia Clinical Site 207

    Sweetwater, Florida

  • Attovia Clinical Site 206

    Indianapolis, Indiana

  • Attovia Clinical Site 202

    Saint Joseph, Missouri

  • Attovia Clinical Site 210

    New York, New York

  • Attovia Clinical Site 102

    Peterborough, Ontario, Canada

  • Altasciences

    Montreal, Quebec, Canada

  • Attovia Clinical Site 301

    Auckland, Auckland, New Zealand

  • Attovia Clinical Site 306

    Auckland, NZ, New Zealand

  • Attovia Clinical Site 304

    Christchurch, NZ, New Zealand

  • Attovia Clinical Site 302

    Hamilton, NZ, New Zealand

  • Attovia Clinical Site 303

    Nelson, NZ, New Zealand

  • Attovia Clinical Site 305

    Wellington, NZ, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.